An insight into salivary markers in oral cancer

Dental Research Journal

Volumn 10, Issue 3, 2013, Pages 287-295

  Krishna Prasad, Ramnarayan Belur ^a   Sharma, Akhilesh ^a   Babu, Harsha Mysore ^b  

^a Oxford Dental College and Hospital   (India)

^b Dayananda Sagar College of Engineering   (India)

Author keywords

DNA markers; oral cancer; protein markers; RNA markers; salivary markers; tumor markers

Indexed keywords

EID: 84903581446     PISSN: 17353327     EISSN: 20080255     Source Type: Journal    
DOI: 10.4103/1735-3327.115127     Document Type: Review

References (82)

1. Myers JN, Elkins T, Roberts D, Byers RM. Squamous cell carcinoma of the tongue in young adults: Increasing incidence and factors that predict treatment outcomes. Otolaryngol Head Neck Surg 2000;122:44 51
2. Sparano A, Weinstein G, Chalian A, Yodul M, Weber R. Multivariate predictors of occult neck metastasis in early oral tongue cancer. Otolaryngol Head Neck Surg 2004;131:472 6
3. Tsantoulis PK, Kastrinakis NG, Tourvas AD, Laskaris G, Gorgoulis VG. Advances in the biology of Oral cancer. Oral Oncol 2007;43:523 34
4. Peacock S, Pogrel A, Schmidt BL. Exploring the reasons for delay in treatment of oral cancer. Am Dent Assoc 2008;139:1346 52
5. Reibel J. Prognosis of oral pre malignant lesions: Significance of clinical, histopathological, and molecular biological characteristics. Crit Rev Oral Biol Med 2003;14:47 62
6. Warnakulasuriya S. Histological grading of oral epithelial dysplasia: Revisited. J Pathol 2001;194:294 7
7. Schwartz JL. Biomarkers and molecular epidemiology and chemoprevention of oral carcinogenesis. Crit Rev Oral Biol Med 2000;11:92 122
8. Nayak AG, Chatra L. Tumor Markers: An overview. JIAOMR 2010;22:147 50
9. Nagler RM, Barak M, Ben Aryeh H, Peled M, Filatov M, Laufer D. Early diagnostic and treatment monitoring role of Cyfra 21 1 and TPS in oral squamous cell carcinoma. Cancer 1999;35:1018 25
10. Bhatavdekar JM, Patel DD, Vora HH, Balar DB. Circulating prolactin and TPS in monitoring the clinical course of male patients with metastatic tongue cancer: A preliminary study. Anticancer Res 1993;13:237 40
11. Yen TC, Lin WY, Kao CH, Cheng KY, Wang SJ. A study of a new tumour marker, CYFRA 21 1, in squamous cell carcinoma of the head and neck, and comparison with squamous cell carcinoma antigen. Clin Otolaryngol 1998;23:82 6
12. Krimmel M, Hoffmann J, Krimmel C, Cornelius CP, Schwenzer N. Relevance of SCC Ag, CEA, CA 19.9, and CA125 for diagnosis and follow up in oral cancer. J Craniomaxillofac Surg 1998;26:243 8
13. Hoffmann J, Munz A, Krimmel M, Alfter G. Intraoperative and postoperative kinetics of serum tumor markers in patients with oral carcinoma. J Oral Maxillofac Surg1998;56:1390 3
14. Nagler R, Bahar G, Shpitzer T, Feinmesser R. Concomitant analysis of salivary tumor markers: A new diagnostic tool for oral cancer. Clin Cancer Res 2006;12:3979 84
15. Chan DW, Sell S. Tumor markers. In: Burtis CA, Ashwood ER, editors. Tietz's textbook of clinical chemistry. 2nd ed. Philadelphia: WB Saunders; 1994. p. 897 925
16. Lehto VP, Ponten J. Tumor markers in human biopsy material. Rev Oncol 1989;28:743 7
17. Rassekh CH, Johnson JT, Eibling DE. Circulating markers in squamous cell carcinoma of the head and neck: A review. Eur J Cancer B Oral Oncol 1994;30:23 8
18. Speight PM, Morgan PR. The natural history and pathology of oral cancer and precancer. Comm Dent Health 1993;10(Suppl 1):31 41
19. William B, Ronald BH. Characteristics of the ideal ztumor marker in holland frei cancer medicine. 6th ed. Hamilton (ON): BC Decker; 2003
20. Kaufman E, Lamster I. The diagnostic applications of saliva: A review. Crit Rev Oral Biol Med 2002;13:197 212
21. Samaranayake L. Saliva as a diagnostic fluid. Int Dent J 2007;57:295 9
22. Miller SM. Saliva testing: A nontraditional diagnostic tool. Clin Lab Sci 1994;7:39 44
23. Hu S, Li Y, Wang J, Xie Y, Tjon K, Wolinsky L, et al. Human saliva proteome and transcriptome. J Dent Res 2006;85:1129 33
24. Bigler LR, Streckfus CF, Dubinsky WP. Salivary biomarkers for the detection of malignant tumors that are remote from the oral cavity. Clin Lab Med 2009;29:71 85
25. Baum BJ. Principles of saliva secretion. Ann NY Acad Sci 1993;694:17 23
26. Haeckel R, Hanecke P. Application of saliva for drug monitoring: An in vivo model for transmembrane transport. Eur J Clin Chem Clin Biochem 1996;34:171 91
27. Aps JK, Martens LC. Review: The physiology of saliva and transfer of drugs into saliva. Forensic Sci Int 2005;150:119 31
28. Halicka HD, Bedner E, Darzynkiewicz Z. Segregation of RNA and separate packaging of DNA and RNA in apoptotic bodies during apoptosis. Exp Cell Res 2000;260:248 56
29. Hasselmann D, Rappl G, Tilgen W, Reinhold U. Extracellular tyrosinase mRNA within apoptotic bodies is protected from degradation in human serum. Clin Chem 2001;47:1488 9
30. Ratajczak J, Wysoczynski M, Hayek F, Janowska Wieczorek A, Ratajczak MZ. Membrane derived microvesicles: Important and underappreciated mediators of cell to cell communication. Leukemia 2006;20:1487 95
31. Simpson RJ, Lim JW, Moritz RL, Mathivanan S. Exosomes: Proteomic insights and diagnostic potential. Expert Rev Proteomics 2009;6:267 83
32. García JM, García V, Peña C, Domínguez G, Silva J, Diaz R, et al. Extracellular plasma RNA from colon cancer patients is confined in a vesicle like structure and is mRNA enriched. RNA 2008;14:1424 32
33. Yuan A, Farber EL, Rapoport AL, Tejada D, Deniskin R, Akhmedov NB, et al. Transfer of microRNAs by embryonic stem cell microvesicles. PLoS One 2009;4:e4722
34. Skog J, Würdinger T, van Rijn S, Meijer DH, Gainche L, Sena Esteves M, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 2008;10:1470 6
35. Simpson RJ, Jensen SS, Lim JW. Proteomic profiling of exosomes: Current perspectives. Proteomics 2008;8:4083 99
36. Al Nedawi K, Meehan B, Rak J. Microvesicles: Messengers and mediators of tumor progression. Cell Cycle 2009;8:2014 8
37. Aharon A, Brenner B. Microparticles, thrombosis and cancer. Best Pract Res Clin Haematol 2009;22:61 9
38. Rajkumar K, Kumar AR, Ramyamalini V, Nandhini G, Kumar TD, Ashwini BK, et al. Estimation of serological and salivary biomarkers in patients with Oral Squamous cell carcinoma, premalignant lesions and conditions. SRM Univ J Dent Sci 2010;1:14 19
39. Markopoulos AK, Michailidou EZ, Tzimagiorgis G. Salivary markers for oral cancer detection. The Open Dent J 2010;4:171 8
40. Lichtenstein AV, Potapova GI. Genetic defects as tumor markers. Mol Biol 2003;37;159 69
41. Sudbo J, Kildal W, Risberg B, Koppang HS, Danielsen HE, Reith A. DNA content as a prognostic marker in patients with oral leukoplakia. N Engl J Med. 2001;344:1270 8
42. Femiano F, Scully C. DNA cytometry of oral leukoplakia and oral lichen planus. Med Oral Patol Oral Cir Bucal 2005;10 (Suppl 1):E9 14
43. Rubio Bueno P, Naval Gias L, García Delgado R, Domingo Cebollada J, Díaz González FJ. Tumor DNA content as a prognostic indicator in squamous cell carcinoma of the oral cavity and tongue base. Head Neck 1998;20:232 9
44. Zhang L, Rosin MP. Loss of heterozygosity: A potential tool in management of oral premalignant lesions? J Oral Pathol Med 2001;30:513 20
45. Califano J, Van der Riet P, Westra W, Nawroz H, Clayman G, Piantadosi S, et al. Genetic progression model for head and neck cancer: Implications for field cancerization. Cancer Res 1996;56:2488 92
46. Lee JJ, Hong WK, Hittelman WN, Mao L, Lotan R, Shin DM, et al. Predicting cancer development in oral leukoplakia: Ten years of translational research. Clin Cancer Res 2000;6:1702 10
47. Partridge M, Pateromichelakis S, Phillips E, Emilion GG, A'Hern RP, Langdon JD. A case control study confirms that microsatellite assay can identify patients at risk of developing oral squamous cell carcinoma within a field of cancerization. Cancer Res 2000;60:3893 8
48. Rosin MP, Cheng X, Poh C, Lam WL, Huang Y, Lovas J, et al. Use of allelic loss to predict malignant risk for low grade oral epithelial dysplasia. Clin Cancer Res 2000;6:357 62
49. Fliss MS, Usadel H, Caballero OL, Wu L, Buta MR, Eleff SM, et al. Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. Science 2000;287:2017 9
50. Wanninayake M Tilakaratne. Oral cavity and major and minor salivary glands. In the cancer handbook. 2nd ed. United States: John Wiley and Sons Ltd; 2007. p. 1 15
51. Boyle JO, Hakim J, Koch W, Van der Riet P, Hruban RH, Roa RA, et al. The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res 1993;53:4477 80
52. Murti PR, Warnakulasuriya KA, Johnson NW, Bhonsle RB, Gupta PC, Daftary DK, et al. p53 expression in oral precancer as a marker for malignant potential. J Oral Pathol Med 1998;27:191 6
53. Shahnavaz SA, Regezi JA, Bradley G, Dubé ID, Jordan RC. p53 gene mutations in sequential oral epithelial dysplasias and squamous cell carcinomas. J Pathol 2000;190:417 22
54. Ha PK, Califano JA. Promoter methylation and inactivation of tumour suppressor genes in oral squamous cell carcinoma. Lancet Oncol 2006;7:77 82
55. Rosas SL, Koch W, Da Costa Carvalho MG, Wu L, Califano J, Westra W, et al. Promoter hypermethylation patterns of p16, O6 methylguanine DNA methyltransferase, and death associated protein kinase in tumors and saliva of head and neck cancer patients. Cancer Res 2001;61:939 42
56. Das BR, Nagpal JK. Understanding the biology of oral cancer. Med Sci Monit 2002;8:RA258 67
57. Vielba R, Bilbao J, Ispizua A, Zabalza I, Alfaro J, Rezola R, et al. p53 and cyclin D1 as prognostic factors in squamous cell carcinoma of the larynx. Laryngoscope 2003;113:167 72
58. Nagpal JK, Mishra R, Das BR. Activation of Stat 3 as one of the early events in tobacco chewing mediated oral carcinogenesis. Cancer 2002;94:2393 400
59. Shpitzer T, Hamzany Y, Bahar G, Feinmesser R, Savulescu D, Borovoi I, et al. Salivary analysis of oral cancer biomarkers. Br J Cancer 2009;101:1194 8
60. Shimakage M, Horii K, Tempaku A, Kakudo K, Shirasaka T, Sasagawa T. Association of Epstein Barr virus with oral cancers. Hum Pathol 2002;33:608 14
61. Eichel HJ, Conger N, Chernick WS. Acid and alkaline ribonucleases of human parotid, submaxillary, and whole saliva. Arch Biochem Biophys 1964;107:197 208
62. Hu Z, Zimmermann BG, Zhou H, Wang J, Henson BS, Yu W, et al. Exon level expression profiling: A comprehensive transcriptome analysis of oral fluids. Clin Chem 2008;54:824 32
63. Wong DT. Salivary diagnostics powered by nanotechnologies, proteomics and Genomics. JADA 2006;137:313 21
64. Zimmermann BG, Wong DT. Salivary mRNA targets for cancer diagnostics. Oral Oncol 2008;44:425 9
65. Hu S, Arellano M, Boontheung P, Wang J, Zhou H, Jiang J, et al. Salivary proteomics for oral cancer biomarker discovery. Clin Cancer Res 2008;14:6246 52
66. Hu S, Yen Y, Ann D, Wong DT. Implications of salivary proteomics in drug discovery and development: A focus on cancer drug discovery. Drug Discov Today 2007;12:911 6
67. Nyström T. Role of oxidative carbonylation in protein quality control and senescence. EMBO J 2005;24:1311 7
68. Shpitzer T, Bahar G, Feinmesser R, Nagler RM. A comprehensive salivary analysis for oral cancer diagnosis. Cancer Res Clin Oncol 2007;133:613 7
69. Pories SE, Zurakowski D, Roy R, Lamb CC, Raza S, Exarhopoulos A et al. Urinary metalloproteinases: Noninvasive biomarkers for breast cancer risk assessment. Cancer Epidemiol Biomarkers Prev 2008;17:1034 42
70. Chen L, Sun B, Zhang S, Zhao X, He Y, Zhao S, et al. Influence of microenvironments on microcirculation patterns and tumor invasion related protein expression in melanoma. Oncol Rep 2009;21:917 23
71. Vairaktaris E, Vassiliou S, Nkenke E, Serefoglou Z, Derka S, Tsigris C, et al. A metalloproteinase 9 polymorphism which affects its expression is associated with increased risk for oral squamous cell carcinoma. Eur J Surg Oncol 2008;34:450 5
72. Pezelj Ribaric S, Prso IB, Abram M, Glazar I, Brumini G, Simunovic Soskic M. Salivary levels of tumor necrosis factor alpha in oral lichen planus. Mediators Inflamm 2004;13:131 3
73. St John MA, Li Y, Zhou X, Denny P, Ho CM, Montemagno C, et al. Interleukin 6 and interleukin 8 as potential biomarkers for oral cavity and oropharyngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2004;130:929 35
74. Rhodus NL, Ho V, Miller CS, Myers S, Ondrey F. NF kappa B dependent cytokine levels in saliva of patients with oral preneoplastic lesions and oral squamous cell carcinoma. Cancer Detect Prev 2005;29:42 5
75. Arellano Garcia ME, Hu S, Wang J, Henson B, Zhou H, Chia D, et al. Multiplexed immunobead based assay for detection of oral cancer protein biomarkers in saliva. Oral Dis 2008;14:705 12
76. Moll R, Franke WW, Schiller DI. The catalog of human cytokeratins: Patterns of expression in normal epithelia, tumors and cultured cells. Cell 1982;31:11 21
77. Lichtenstein A, Ganz T, Selsted ME, Lehrer RI. In vitro tumor cell cytolysis mediated by peptide defensins of human and rabbit granulocytes. Blood 1986;68:1407 10
78. Lehrer RI, Ganz T, Selsted ME. Defensins: Endogenous antibiotic peptides of animal cells. Cell 1991;64:229 30
79. Mizukawa N, Sugiyama K, Fukunaga J, Ueno T, Mishima K, Takagi S, et al. Defensin 1, a peptide detected in the saliva of oral squamous cell carcinoma patients. Anticancer Res 1998;18:4645 9
80. Kurokawa H, Tsuru S, Okada M, Nakamura T, Kajiyama M. Evaluation of tumor markers in patients with squamous cell carcinoma in the oral cavity. Int J Oral Maxillofac Surg 1993;22:35 8
81. Kurokawa H, Yamashita Y, Tokudome S, Kajiyama M. Combination assay for tumor markers in oral squamous cell carcinoma. J Oral Maxillofac Surg 1997;55:964 6
82. Bahar G, Feinmesser R, Shpitzer T, Popovtzer A, Nagler RM. Salivary analysis in oral cancer patients DNA and protein oxidation, reactive nitrogen species and antioxidant profile. Cancer 2007;109:54 9